Immunotherapy Landscape in Prostate Cancer: Successes, Failures and Promises
annals of urologic oncology · 2019
DOI: 10.32948/auo.2019.09.04 ↗Kurz gefasst
Fachartikel in der Zeitschrift annals of urologic oncology, 2019. Verfasst von Sabeeh‑ur‑Rehman Butt und 5 weiteren Autor:innen. Die Arbeit nennt 129 Literaturangaben.
Abstract (Originalsprache)
As research focus in oncology has recently shifted to immunomodulation, the era of introduction of immunotherapeutic agents in the management of prostate cancer has just begun. With the success of checkpoint blockade drugs in certain advanced tumours, ongoing efforts are aimed at identification and validation of new actionable immune targets to consolidate and expand the initial success in other tumour types. In this paper, we review the immunotherapy research in the management of prostate cancer to date, as well as the various emerging immunotherapeutic agents and their possible use. Although monotherapy has thus far had disappointing results in prostate cancer, promising combination strategies are under evaluation.
Zitieren
APA
Butt, S., Khan, M. S., Murias, C., Gonzalez-Exposito, M. R., Arkenau, H., & Patrikidou, A. (2019). Immunotherapy Landscape in Prostate Cancer: Successes, Failures and Promises. annals of urologic oncology. https://doi.org/10.32948/auo.2019.09.04
Vancouver
Butt S, Khan MS, Murias C, Gonzalez-Exposito MR, Arkenau H, Patrikidou A. Immunotherapy Landscape in Prostate Cancer: Successes, Failures and Promises. annals of urologic oncology. 2019. doi:10.32948/auo.2019.09.04
BibTeX
@article{Butt2019,
author = {Butt, Sabeeh‑ur‑Rehman and Khan, Muhammad S and Murias, Carmen and Gonzalez-Exposito, Maria Reyes and Arkenau, Hendrik-Tobias and Patrikidou, Anna},
title = {Immunotherapy Landscape in Prostate Cancer: Successes, Failures and Promises},
journal = {annals of urologic oncology},
year = {2019},
doi = {10.32948/auo.2019.09.04}
}
EUVIMED